Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma

Diffuse large B‐cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current treatment, R‐CHOP, which consists of a cancer drug combination supplemented with the humanized CD20‐targeting monoclonal antibody rituximab. Despite i...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, Emil Aagaard, Rovsing, Anne Bruun, Anderson, Mads Valdemar, Due, Hanne, Huang, Jinrong, Luo, Yonglun, Dybkær, Karen, Mikkelsen, Jacob Giehm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463323/
https://www.ncbi.nlm.nih.gov/pubmed/32585766
http://dx.doi.org/10.1002/1878-0261.12753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463323/
https://www.ncbi.nlm.nih.gov/pubmed/32585766
http://dx.doi.org/10.1002/1878-0261.12753

Ejemplares similares